《大行報告》花旗料比亞迪(01211.HK)次季純利按季增25-30% 開展90日正面催化劑觀察
花旗發表研究報告,料比亞迪(01211.HK)今年次季純利介乎50億至57億元人民幣,按季升25%至30%,每車輛純利料介乎7,500至8,000元人民幣,較首季介乎7,000至7,500元人民幣按季改善。該行料其交付量持續按月改善,邁向全年銷量300萬輛的目標。
據該行向經銷商調查顯示,截至6月底,比亞迪未交付積壓訂單介乎25萬至28萬輛,另料出口進一步加快,上半年出口量料7萬輛,下半年料加快至13萬輛。
該行對比亞迪展開90日正面催化劑觀察,評級「買入」,目標價602元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.